• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii

  1. C. POTHOULAKIS

Article first published online: 23 JUL 2009

DOI: 10.1111/j.1365-2036.2009.04102.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 30, Issue 8, pages 826–833, October 2009

Additional Information

How to Cite

POTHOULAKIS, C. (2009), Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 30: 826–833. doi: 10.1111/j.1365-2036.2009.04102.x

Author Information

  1. Division of Digestive Diseases, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

*Dr C. Pothoulakis, MRL1240, 675 Charles E. Young Drive South, Inflammatory Bowel Disease Center, Division of Digestive Diseases, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA. E-mail: cpothoulakis@mednet.ucla.edu

Publication History

  1. Issue published online: 16 SEP 2009
  2. Article first published online: 23 JUL 2009
  3. Publication data Submitted 10 April 2009 First decision 28 April 2009 Resubmitted 17 July 2009 Accepted 20 July 2009 Epub Accepted Article 23 July 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (219K)

References

  • 1
    Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008; 263: 591–6.
  • 2
    Pallone F, Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr Opin Gastroenterol 2001; 17: 307–12.
  • 3
    Naumann M. Nuclear factor-kappa B activation and innate immune response in microbial pathogen infection. Biochem Pharmacol 2000; 60: 1109–14.
  • 4
    Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13–20.
  • 5
    Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649–83.
  • 6
    Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280–8.
  • 7
    Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451–62.
  • 8
    Jobin C, Sartor RB. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000; 6: 206–13.
  • 9
    Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003; 9: 1107–13.
  • 10
    Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9: 180–6.
  • 11
    Craig R, Larkin A, Mingo AM, et al. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000; 275: 23814–24.
  • 12
    Zhao Q, Lee FS. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J Biol Chem 1999; 274: 8355–8.
  • 13
    Eckmann L, Kagnoff MF, Fierer J. Epithelial cells secrete the chemokine interleukin-8 in response to bacterial entry. Infect Immun 1993; 61: 4569–74.
  • 14
    Goosney DL, DeVinney R, Finlay BB. Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals. Infect Immun 2001; 69: 3315–22.
  • 15
    Dahan S, Busuttil V, Imbert V, Peyron JF, Rampal P, Czerucka D. Enterohemorrhagic Escherichia coli infection induces interleukin-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in T84 cells. Infect Immun 2002; 70: 2304–10.
  • 16
    Berin MC, Darfeuille-Michaud A, Egan LJ, Miyamoto Y, Kagnoff MF. Role of EHEC O157:H7 virulence factors in the activation of intestinal epithelial cell NF-kappaB and MAP kinase pathways and the upregulated expression of interleukin 8. Cell Microbiol 2002; 4: 635–48.
  • 17
    Gobert AP, Vareille M, Glasser AL, Hindre T, De Sablet T, Martin C. Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J Immunol 2007; 178: 8168–74.
  • 18
    Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 2003; 71: 766–73.
  • 19
    Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343: 69–76.
  • 20
    Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11: 142–201.
  • 21
    Hecht GA. Early enterocyte responses to enteropathogenic E. coli. J Pediatr Gastroenterol Nutr 2005; 40(Suppl 1): S32.
  • 22
    Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 1999; 42: 261–4.
  • 23
    Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000; 68: 5998–6004.
  • 24
    Canil C, Rosenshine I, Ruschkowski S, Donnenberg MS, Kaper JB, Finlay BB. Enteropathogenic Escherichia coli decreases the transepithelial electrical resistance of polarized epithelial monolayers. Infect Immun 1993; 61: 2755–62.
  • 25
    Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 2006; 60: 24–9.
  • 26
    Pothoulakis C, Lamont JT. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001; 280: G178–83.
  • 27
    McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
  • 28
    Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108–15.
  • 29
    Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64: 5225–32.
  • 30
    Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302–7.
  • 31
    Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 2762–5.
  • 32
    Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390–7.
  • 33
    Jefferson KK, Smith MF Jr, Bobak DA. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 1999; 163: 5183–91.
  • 34
    He D, Sougioultzis S, Hagen S, et al. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 2002; 122: 1048–57.
  • 35
    Warny M, Keates AC, Keates S, et al. A p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 2000; 105: 1147–56.
  • 36
    Kim H, Kokkotou E, Na X, et al. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 2005; 129: 1875–88.
  • 37
    Chen X, Kokkotou EG, Mustafa N, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006; 281: 24449–54.
  • 38
    Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165: 903–14.
  • 39
    Singer M, Sansonetti PJ. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 2004; 173: 4197–206.
  • 40
    Rodrigues ACP, Nardi RM, Bambirra EA, Vieira EC, Nicoli JR. Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 1996; 81: 251–6.
  • 41
    Mumy KL, Chen X, Kelly CP, McCormick BA. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 2008; 294: G599–609.
  • 42
    Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea--a pilot study. Z Gastroenterol 1993; 31: 129–34.
  • 43
    Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000; 45: 1462–4.
  • 44
    Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697–8.
  • 45
    Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The Effect of Saccharomyces boulardii on Human Colon Cells and Inflammation in Rats with Trinitrobenzene Sulfonic Acid-Induced Colitis. Dig Dis Sci 2008; 54: 255–63.
  • 46
    Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55: 1341–9.
  • 47
    Lee SK, Kim HJ, Chi SG, et al. [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells]. Korean J Gastroenterol 2005; 45: 328–34.
  • 48
    Jawhara S, Poulain D. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 2007; 45: 691–700.
  • 49
    Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008; 14: 390–400.
  • 50
    Mundy R, MacDonald TT, Dougan G, Frankel G, Wiles S. Citrobacter rodentium of mice and man. Cell Microbiol 2005; 7: 1697–706.
  • 51
    Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115–8.
  • 52
    Eckmann L. Animal models of inflammatory bowel disease: lessons from enteric infections. Ann N Y Acad Sci 2006; 1072: 28–38.
  • 53
    Wu X, Vallance BA, Boyer L, et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 2008; 294: G295–306.
  • 54
    Frankel G, Phillips AD, Trabulsi LR, Knutton S, Dougan G, Matthews S. Intimin and the host cell – is it bound to end in Tir(s)? Trends Microbiol 2001; 9: 214–8.
  • 55
    Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131: 1812–25.
  • 56
    Fiocchi C. Probiotics in inflammatory bowel disease: yet another mechanism of action? Gastroenterology 2006; 131: 2009–12.
  • 57
    Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol 2008; 42(Suppl 3 Pt 1): S111–5.
View Full Article (HTML) Get PDF (219K)